TECOGEN INC. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on December 28, 2015, with a report date of December 31, 2015. Tecogen Inc. (Delaware) entered into a material definitive agreement to form a joint venture (JV) named Ultra Emissions Technologies Ltd., organized under the laws of Jersey, Channel Islands. The JV is designed to develop and commercialize Tecogen's patented Ultera Technology for reducing harmful emissions from fossil fuel engines in mobile vehicles.
Key Financial Metrics and Transaction Details
- Joint Venture Capitalization: Tecogen received a 50% equity interest in the JV in exchange for a fully paid-up worldwide license to its Ultera Technology. The remaining 50% equity was purchased by a group of offshore investors for $3,000,000.
- Related Equity Financing: In a related transaction, the same offshore investors purchased 890,208 shares of Tecogen common stock and warrants to purchase 900,000 shares for an aggregate price of $3,000,000.
- Transaction Terms: The purchase price per unit was $3.37. The warrants have an exercise price of $4.00 per share and expire in six months.
- Use of Proceeds: Funds raised will be used for general corporate and working capital purposes.
- Financial Statements: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the company.
Material Changes and Management Commentary
The primary material change is the strategic expansion into mobile vehicle emissions control via the new JV. Robert Panora, Tecogen's President and COO, will serve as co-CEO of the JV alongside Dr. Elias Samaras. The agreement includes a provision that if the venture is not successful, all licensed intellectual property rights will revert to Tecogen. Warrants to purchase additional equity in the JV were granted to all parties pro rata.
Risks and Contingencies
- Success Contingency: The retention of intellectual property rights by Tecogen is contingent on the venture's lack of success.
- Regulatory Status: The sale of Tecogen shares and warrants was conducted as a private placement without registration under the Securities Act of 1933, relying on exemptions under Section 4(a)(2) and/or Regulation D.
Investor Verification Checklist
- Verify the specific terms of the Joint Venture Agreement and License Agreement filed as Exhibits 10.31 and 10.32.
- Confirm the identity and background of the offshore investors and Dr. Elias Samaras.
- Review the press release (Exhibit 99.1) for additional context on the commercialization strategy.
- Monitor the exercise of the 900,000 warrants expiring in six months at $4.00 per share.
- Assess the impact of the $3,000,000 capital raise on Tecogen's working capital position.